<DOC>
	<DOCNO>NCT00004311</DOCNO>
	<brief_summary>OBJECTIVES : I . Evaluate insulin resistance thin obese hyperandrogenic woman polycystic ovarian disease hyperandrogenism insulin resistance acanthosis nigricans syndrome thin obese control , use estimation tissue sensitivity insulin . II . Evaluate effect androgen suppression leuprolide acetate spironolactone insulin secretion resistance .</brief_summary>
	<brief_title>Phase II Study Effect Leuprolide Acetate Spironolactone Insulin Resistance Hyperandrogenic Women With Polycystic Ovarian Disease Hyperandrogenism Insulin Resistance Acanthosis Nigricans Syndrome</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Participants treat subcutaneous leuprolide acetate follow oral spironolactone . Each treatment administer daily 6 week , 6-week washout drug . Patients control alternately assign begin treatment leuprolide acetate spironolactone .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Acanthosis Nigricans</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Polycystic ovarian disease Oligomenorrhea amenorrhea Hirsutism Hyperandrogenism Hyperandrogenism insulin resistance acanthosis nigricans syndrome Hyperandrogenism Oligomenorrhea amenorrhea Insulin resistance Acanthosis nigricans Hematocrit least 30 % Women normal menstrual cycle use oral contraception enter control</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2000</verification_date>
	<keyword>acanthosis nigricans</keyword>
	<keyword>dermatologic disorder</keyword>
	<keyword>endocrine disorder</keyword>
	<keyword>polycystic ovarian syndrome</keyword>
	<keyword>rare disease</keyword>
</DOC>